NCT04767750

Role of LncRNA H19 in The Regulation of IGF-1R Expression

Completed Last updated 7 April 2022

What this trial tests

trial testing Blood sample collection in Hepatocellular Carcinoma in 101 participants. Completed in 4 April 2022.

Timeline

1 January 2020

Primary endpoint
30 January 2022

4 April 2022

Quick facts

Lead sponsor	Mansoura University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	101
Start date	1 January 2020
Primary completion	30 January 2022
Estimated completion	4 April 2022
Sites	2 locations across Egypt

Drugs / interventions tested

• Blood sample collection — full drug profile →

Conditions studied

• Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
• Type 2 Diabetes — all drugs for Type 2 Diabetes →
• Cancer — all drugs for Cancer →

Sponsor

Mansoura University

Who can join

40 and older, any sex, with Hepatocellular Carcinoma or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma (HCC) is a common cancer that poses a heavy economic burden on the healthcare system. In Egypt, it is the most common cause of mortality and morbidity-related cancer. Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia. Cancer and type II diabetes (T2DM), the world's two most prevalent diseases, share many overlapping risk factors and predisposing pathological conditions. The exact mechanisms linking those two diseases are yet to be fully understood.

In this study, the investigators aim to assess the relationship between Long Non-Coding RNA (lncRNA) H19 and Insulin-Like Growth Factor 1 Receptor (IGF-1R) mRNA gene expressions in the blood samples of HCC \& T2DM patients to investigate the probability of the presence of a pathophysiological link between HCC and DM that may become a therapeutic target for both diseases. To the investigator's knowledge, there is currently no human research study investigating both H19 and IGF-1R in both DM and cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
   Jiang W, Pan S, Chen X, Wang ZW, et al · · 2021 · cited 124× · PMID 34496886 · DOI 10.1186/s12943-021-01406-7
2. Metabolic memory: mechanisms and diseases.
   Dong H, Sun Y, Nie L, Cui A, et al · · 2024 · cited 62× · PMID 38413567 · DOI 10.1038/s41392-024-01755-x
3. Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications.
   Khanbabaei H, Ebrahimi S, García-Rodríguez JL, Ghasemi Z, et al · · 2022 · cited 36× · PMID 36114510 · DOI 10.1186/s13046-022-02488-x
4. Non-coding RNAs as therapeutic targets in cancer and its clinical application.
   Leng X, Zhang M, Xu Y, Wang J, et al · · 2024 · cited 20× · PMID 39149142 · DOI 10.1016/j.jpha.2024.02.001
5. The Involvement of Long Non-Coding RNAs in Glioma: From Early Detection to Immunotherapy.
   Wu X, Yang L, Wang J, Hao Y, et al · · 2022 · cited 18× · PMID 35619711 · DOI 10.3389/fimmu.2022.897754
6. Circulating Long Non-Coding RNAs Could Be the Potential Prognostic Biomarker for Liquid Biopsy for the Clinical Management of Oral Squamous Cell Carcinoma.
   Dey Ghosh R, Guha Majumder S. · · 2022 · cited 17× · PMID 36428681 · DOI 10.3390/cancers14225590
7. Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis.
   Wade H, Pan K, Zhang B, Zheng W, et al · · 2024 · cited 14× · PMID 39872125 · DOI 10.1136/egastro-2024-100115
8. Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery.
   Pandey A, Ajgaonkar S, Jadhav N, Saha P, et al · · 2022 · cited 14× · PMID 36297381 · DOI 10.3390/ph15101269